Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced, NSCLC and Urothelial Cancer
Condition: Unresectable Non-small Cell Lung Cancer (NSCLC) and Urothelial Cancer Intervention: Drug: Durvalumab Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | India Health | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study